other outcomes, return to heavy drinking, GGT and side effectsindividuals with alcohol dependence, under DSM‐IV‐TR/ICD‐10acamprosate, as adjunctive to psychosocial/psychotherapeuticacamprosate and naltrexone comparison, for relative effectivenessdoi:10.1002/9781118454503.ch12Iosief AbrahaCristina CusiJohn Wiley & Sons, Ltd
alcoholismalcohol relapseglutamate systemmeta-analysisrandomized controlled trialsAcamprosate, calcium acetyl homotaurinate, was first developed and tested in the early 1980s in France and has been available in the USA since 2004. Its major mechanism of action is the reduction of cerebral hyper...
Disulfiram deters alcohol consumption by inducing severe side effects upon alcohol use, making it suitable for closely monitored AUD patients with a strong motivation to maintain sobriety (Kalra et al., 2014;Vol., Skinner et al., 2014). Acamprosate and naltrexone are commonly characterized as anti...
Acamprosate and its efficacy in treating alcohol dependent adolescentsdoi:10.1007/s00787-003-0327-1Background: About 50 % of adult alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that acamprosate may help to prevent such relapse. The aim of our study was ...
Alcohol misuse accounts for a sizeable proportion of the global burden of disease, and Campral® (acamprosate; calcium-bis-(N-acetylhomotaurinate)) is widely used as relapse prevention therapy. The mechanism underlying its effect has in some studies be
Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known tha
Thus in this study acamprosate proved to be a safe and effective aid for maintaining abstinence in the treatment of a alcohol-dependence. In addition to these results the data set of the study was further analysed to get information about several clinical and research issues, e.g. if there ...
Objectives: Acamprosate and naltrexone are the only two drugs approved by the US Food and Drug Administration for achieving abstinence in patients with Alcohol Dependence Syndrome. Acamprosate is well tolerated and has a few drug interactions. It has a comparatively benign side effect profile which ...
Objective: This study was undertaken to evaluate the efficacy and safety of acamprosate in the treatment of alcohol dependence. Method: The investigation was a double-blind, placebo-controlled, 24- week study carried out at the University of S茫o Paulo, Brazil. The sample comprised 75 patients,...
However, overall compliance was relatively low with both medications. CONCLUSIONS: Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults. Acamprosate appears to be especially useful in a therapeutic approach targeted at achiev...